N | Age (mean) | Age (range) | HPV positive | % | HPV negative | % | HPV single | % | HPV multiple | % | hrHPV* pos. | % | |
CIN1 | 40 | 32.7 | (20–51) | 31 | 77.5 | 9 | 22.5 | 21 | 67.7 | 10 | 32.3 | 24 | 77.4 |
CIN2 | 39 | 34.4 | (19–72) | 35 | 89.7 | 4 | 10.3 | 27 | 77.1 | 8 | 22.9 | 34 | 97.1 |
CIN3 | 41 | 38.6 | (25–74) | 39 | 95.1 | 2 | 4.9 | 31 | 79.5 | 8 | 20.5 | 39 | 100.0 |
Cancer (ICC) | 104 | 52.6 | (27–86) | 92 | 88.5 | 3 | 20.0 | 87 | 94.6 | 5 | 5.4 | 86 | 93.5 |
SCC+ASC | 89 | 52.2 | (27–86) | 80 | 89.9 | 9 | 10.1 | 75 | 93.8 | 5 | 6.3 | 74 | 92.5 |
ADC | 15 | 51.9 | (32–74) | 12 | 80.0 | 12 | 11.5 | 12 | 100.0 | 0 | 0 | 12 | 100.0 |
↵*Percentage of hrHPV is calculated from the number of HPV-positive cases.
ADC, adenocarcinomae; ASC, adenosquamous carcinoma; CIN, cervical intraepithelial neoplasia; ICC, invasive cervical cancer; SCC, squamous cell carcinoma.